Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ARQL > SEC Filings for ARQL > Form 8-K on 4-Feb-2014All Recent SEC Filings

Show all filings for ARQULE INC

Form 8-K for ARQULE INC


4-Feb-2014

Other Events, Financial Statements and Exhibits


Item 8.01 Other Events.

On February 4, 2014, ArQule, Inc. (the "Registrant") reported the announcement by its development partner, Kyowa Hakko Kirin Co., Ltd., of the initiation of a Phase 3 clinical trial evaluating tivantinib (ARQ 197) in Japanese patients with c-Met diagnostic-high inoperable hepatocellular carcinoma treated with one prior sorafenib therapy.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1 Text of press release dated February 4, 2014 reporting Phase 3 clinical trial initiation.

  Add ARQL to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ARQL - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.